Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | ITK | Q08881 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.88 |
| ▸ | ABL1 | P00519 | 13/20 | 0.78 |
| ▸ | BCR | P11274 | 12/20 | 0.78 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.78 |
| ▸ | KDR | P35968 | 4/20 | 0.74 |
| ▸ | KIT | P10721 | 1/20 | 0.73 |
| ▸ | PRKCA | P17252 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317193 | 0.94 | PDGFRA (1.00) | EGFRJAK3BTKITKPDGFRA | |
| SCHEMBL5050327 | 0.91 | PDGFRA (0.89) | EGFRJAK3BTKITKPDGFRA | |
| SCHEMBL11927817 | 0.91 | PDGFRA (0.92) | EGFRJAK3BTKITKPDGFRA | |
| SCHEMBL11927826 | 0.90 | PDGFRA (0.87) | EGFRJAK3BTKITKPDGFRA | |
| SCHEMBL23246300 | 0.89 | ABL1 (0.86) | EGFRJAK3BTKITKPDGFRA | |
| SCHEMBL19556857 | 0.88 | ABL1 (1.00) | EGFRJAK3BTKITKPDGFRA | |
| SCHEMBL14979762 | 0.87 | EGFR (0.77) | EGFRJAK3BTKITKPDGFRA | |
| Cyclohexane SCHEMBL5776157 | 0.86 | ABL1 (0.81) | EGFRJAK3BTKITKPDGFRA | |
| SCHEMBL3636349 | 0.86 | PDGFRA (1.00) | EGFRJAK3BTKITKPDGFRA | |
| SCHEMBL11927765 | 0.85 | PDGFRA (1.00) | EGFRJAK3BTKITKPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| EP-2361248-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| CN-102083800-A | Heteroaryl compounds and uses thereof | AVILA THERAPEUTICS AND USES TH | 2011-06-01 | — | — | CN | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885JAK3 439/4885BTK 594/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885JAK3 439/4885BTK 594/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | EGFR 460/4885JAK3 155/4885BTK 261/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885JAK3 439/4885BTK 594/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | EGFR 176/4885JAK3 169/4885BTK 149/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885JAK3 439/4885BTK 594/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | EGFR 460/4885JAK3 155/4885BTK 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.